DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • South Korea
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
A195940 logo

HK inno.N Corporation Stock Price

KOSDAQ:A195940 Community·₩1.2t Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

A195940 Share Price Performance

₩40,700.00
-5500.00 (-11.90%)
​
₩40,700.00
-5500.00 (-11.90%)
​
Price ₩40,700.00
Sat, 12 Sep 26
Share Pricen/a

A195940 Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Overvalued with concerning outlook.

0 Risks
2 Rewards
View Full Analysis

HK inno.N Corporation Key Details

₩839.6b

Revenue

₩491.4b

Cost of Revenue

₩348.2b

Gross Profit

₩306.7b

Other Expenses

₩41.5b

Earnings

Last Reported Earnings
Sep 30, 2022
Next Reporting Earnings
n/a
0
0%
0%
0%
View Full Analysis

About A195940

Founded
1984
Employees
n/a
CEO
Dal-Won Kwak
WebsiteView website
www.inno-n.com

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer; and nutrition and intravenous nutrition. It also provides health and beverage products, such as hangover relief, ready to drink, health supplements and health functional foods, as well as active pharmaceutical ingredients. In addition, the company offers beauty products under the bewants, ScalpMed, and KLEDERMA RX brands. It also exports its products to Japan, Southeast Asia, Latin America, Europe, and the Middle East countries. The company has joint research and development agreement with Nextgen Bioscience for NXC680, a candidate compound for treatment of Idiopathic Pulmonary Fibrosis. HK inno.N Corporation was founded in 1984 and is headquartered in Cheongju-si, South Korea.

Recent A195940 News & Updates

Recent updates

No updates

HK inno.N Corporation Competitors

A207940 logo

Samsung BiologicsLtd

Symbol: KOSE:A207940
Market cap: ₩65.4t
A068270 logo

Celltrion

Symbol: KOSE:A068270
Market cap: ₩42.8t
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide